Prospective randomized phase II trial of oral vinorelbine (NVBo) and cisplatin (P) or pemetrexed (Pem) and P in first-line metastatic or locally advanced non-small cell lung cancer (M or LA NSCLC) patients (pts) with nonsquamous (non SCC) histologic type: NAVoTRIAL01—Preliminary results.
Jaafar Bennouna
Consultant or Advisory Role - Amgen; Boehringer Ingelheim; Roche
Petr Zatloukal
No relevant relationships to disclose
Maciej Jerzy Krzakowski
No relevant relationships to disclose
Jens Kollmeier
Consultant or Advisory Role - Boehringer Ingelheim (U); Lilly (U); Roche (U)
Alain Riviere
No relevant relationships to disclose
Eric Dansin
No relevant relationships to disclose
Monika Serke
Employment or Leadership Position - Lungenklinik Hemer
Consultant or Advisory Role - Fa Lilly
Honoraria - Fa Lilly
Adolfo G. Favaretto
No relevant relationships to disclose
Libor Havel
No relevant relationships to disclose
Stephanie Malasse
Employment or Leadership Position - Pierre Fabre Medicament
Fabienne Biville-Hedouin
Employment or Leadership Position - Pierre Fabre Medicament
Eng Huat Tan
No relevant relationships to disclose